LONDON, ENGLAND, 28 November, 2006 - SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) today announces that Solaraze(R), its topical 3% gel (diclofenac sodium) treatment for actinic keratosis, has been approved for registration by the Australian Government Department of Health and Ageing Therapeutic Goods Administration (TGA).
